Clinical Trial

Brain NAD in Alzheimer's Disease

Study acronym: ALZNAD
Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this observational study is to learn about the levels of nicotinamide adenine dinucleotide (NAD) in the brains of people with Alzheimer's disease. The study aims to determine if brain NAD levels are lower in people with Alzheimer's disease compared with people of the same age group who do not have Alzheimer's disease. Participants with or without Alzheimer's disease will have a brain imaging session where NAD will be measured using magnetic resonance spectroscopy (MRS). Eight months later, they will have a second, similar, brain imaging session.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-08-11; most recent amendment 2026-03-21.
Status change: Not Yet Recruiting → Recruiting 2025-12-09
Trial Details
NCT Number NCT07127510
Lead Sponsor Florida Atlantic University
Conditions Alzheimer Disease (AD)
Enrollment 20 participants
Start Date 2026-03-18
Primary Completion 2027-04-01 (estimated)
Study Completion 2027-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-24